Deakin University
Browse

File(s) under permanent embargo

An Australian experience with temozolomide for the treatment of recurrent high grade gliomas

journal contribution
posted on 2001-07-01, 00:00 authored by M T Harris, M A Rosenthal, David Ashley, L Cher
Temozolomide has an evolving role in the treatment of high grade gliomas. Recent studies suggest that temozolomide is well tolerated and efficacious. This study retrospectively analysed the activity and toxicity associated with temozolomide at two Australian centres over a 24 month period. Fifty-six patients with recurrent high grade gliomas were treated with temozolomide. Patients received temozolomide orally at 150-200mg/m(2)daily, days 1-5, every 4 weeks. The median number of treatment cycles was 4 (1-12). Of the 56 patients, 15 (27%) achieved complete or partial response and 18 (32%) achieved minor response or stable disease. There were no episodes of febrile neutropenia and temozolomide was generally well tolerated. In conclusion, temozolomide is an active therapy in patients with recurrent high grade glioma and our results concord with published studies.

History

Journal

Journal of clinical neuroscience

Volume

8

Issue

4

Pagination

325 - 327

Publisher

Elsevier

Location

Amsterdam, The Netherlands

ISSN

0967-5868

Language

eng

Publication classification

CN.1 Other journal article

Copyright notice

2001, Harcourt Publishers

Usage metrics

    Research Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC